Aquinox Pharmaceuticals Company Profile (NASDAQ:AQXP)

About Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals logoAquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AQXP
  • CUSIP: N/A
  • Web:
  • Market Cap: $333.43 million
  • Outstanding Shares: 23,423,000
Average Prices:
  • 50 Day Moving Avg: $14.42
  • 200 Day Moving Avg: $15.34
  • 52 Week Range: $8.76 - $19.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.08
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.31 per share
  • Price / Book: 2.73
  • Return on Equity: -29.54%
  • Return on Assets: -27.88%
  • Current Ratio: 16.28%
  • Quick Ratio: 16.28%
  • Average Volume: 64,209 shs.
  • Beta: -17.03
  • Short Ratio: 21.38

Frequently Asked Questions for Aquinox Pharmaceuticals (NASDAQ:AQXP)

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) issued its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.59). View Aquinox Pharmaceuticals' Earnings History.

Where is Aquinox Pharmaceuticals' stock going? Where will Aquinox Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 12-month price targets for Aquinox Pharmaceuticals' stock. Their predictions range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' share price to reach $24.67 in the next year. View Analyst Ratings for Aquinox Pharmaceuticals.

Who are some of Aquinox Pharmaceuticals' key competitors?

Who are Aquinox Pharmaceuticals' key executives?

Aquinox Pharmaceuticals' management team includes the folowing people:

  • David J. Main, Co-Founder, President and Chief Executive Officer and Chairman of the Board
  • Kamran Alam, Chief Financial Officer, Vice President - Finance
  • Lloyd Mackenzie, Vice President - Technical Operations and Planning
  • David Chilton Mitchell, Vice President - Global Regulatory Affairs & Quality Assurance
  • Barbara Troupin M.D., Chief Medical Officer, Vice President - Clinical Development
  • Robert E. Pelzer, Lead Independent Director
  • Gary J. Bridger Ph.D., Director
  • Daniel J. Levitt M.D., Ph.D., Director
  • Richard S. Levy M.D., Director
  • Kelvin M. Neu M.D., Director

Who owns Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include RA Capital Management LLC (5.96%), Franklin Resources Inc. (5.64%), Goldman Sachs Group Inc. (4.11%), Vanguard Group Inc. (1.21%), Royce & Associates LP (0.62%) and Emory University (0.45%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker, David Chilton Mitchell and David Main. View Institutional Ownership Trends for Aquinox Pharmaceuticals.

Who sold Aquinox Pharmaceuticals stock? Who is selling Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Emory University, Goldman Sachs Group Inc., D.A. Davidson & CO. and ProShare Advisors LLC. View Insider Buying and Selling for Aquinox Pharmaceuticals.

Who bought Aquinox Pharmaceuticals stock? Who is buying Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Sphera Funds Management LTD., Vanguard Group Inc., Archon Partners LLC, Bank of New York Mellon Corp, Northern Trust Corp and Alps Advisors Inc.. Company insiders that have bought Aquinox Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and David Chilton Mitchell. View Insider Buying and Selling for Aquinox Pharmaceuticals.

How do I buy Aquinox Pharmaceuticals stock?

Shares of Aquinox Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquinox Pharmaceuticals' stock price today?

One share of Aquinox Pharmaceuticals stock can currently be purchased for approximately $14.48.

MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aquinox Pharmaceuticals (NASDAQ:AQXP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.67 (70.35% upside)

Analysts' Ratings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Canaccord GenuitySet Price TargetBuy$22.00HighView Rating Details
5/9/2017Cantor FitzgeraldSet Price TargetBuy$28.00LowView Rating Details
11/11/2016Leerink SwannReiterated RatingBuy$24.00N/AView Rating Details
11/10/2016Needham & Company LLCReiterated RatingBuyN/AView Rating Details
8/5/2016Jefferies Group LLCBoost Price TargetHold$7.00 -> $9.00N/AView Rating Details
11/3/2015Cowen and CompanyReiterated RatingBuy$23.00N/AView Rating Details
10/6/2015GuggenheimInitiated CoverageBuy$22.00N/AView Rating Details
(Data available from 8/18/2015 forward)


Earnings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Earnings by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Earnings History by Quarter for Aquinox Pharmaceuticals (NASDAQ AQXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/20176/30/2017($0.59)($0.59)ViewListenView Earnings Details
5/9/20173/31/2017($0.51)($0.36)ViewN/AView Earnings Details
3/9/201712/31/2016($0.51)($0.48)ViewListenView Earnings Details
11/9/2016Q316($0.58)($0.46)ViewN/AView Earnings Details
8/4/2016Q2($0.41)($0.63)ViewN/AView Earnings Details
5/10/2016Q1($0.35)($0.39)ViewN/AView Earnings Details
11/10/2015Q315($0.45)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.56)($0.44)ViewN/AView Earnings Details
5/12/2015Q115($0.83)($0.60)ViewN/AView Earnings Details
4/15/2015($0.57)($0.78)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.76)($0.78)ViewN/AView Earnings Details
11/4/2014Q3 2014($0.29)($0.59)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.27)($0.51)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)
2017 EPS Consensus Estimate: ($2.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.57)($0.57)($0.57)
Q2 20171($0.59)($0.59)($0.59)
Q3 20171($0.62)($0.62)($0.62)
Q4 20171($0.65)($0.65)($0.65)
(Data provided by Zacks Investment Research)


Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 98.20%
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/5/2017David MainInsiderSell15,625$13.26$207,187.50View SEC Filing  
1/9/2017Bros. Advisors Lp BakerMajor ShareholderBuy398,062$17.18$6,838,705.16View SEC Filing  
9/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy2,783,605$12.25$34,099,161.25View SEC Filing  
3/16/2016Bros. Advisors Lp BakerMajor ShareholderBuy471,667$7.99$3,768,619.33View SEC Filing  
3/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy109,912$7.98$877,097.76View SEC Filing  
1/26/2016Bros. Advisors Lp BakerMajor ShareholderBuy140,786$10.80$1,520,488.80View SEC Filing  
1/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy112,034$9.48$1,062,082.32View SEC Filing  
1/19/2016Bros. Advisors Lp BakerMajor ShareholderBuy78,045$9.11$710,989.95View SEC Filing  
1/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy202,623$8.28$1,677,718.44View SEC Filing  
9/10/2015Bros. Advisors Lp BakerMajor ShareholderBuy2,480,032$15.50$38,440,496.00View SEC Filing  
8/24/2015David Chilton MitchellVPBuy3,575$17.81$63,670.75View SEC Filing  
8/12/2015Kamran AlamCFOSell29,079$18.67$542,904.93View SEC Filing  
8/12/2015Lloyd MackenzieVPSell35,887$18.67$670,010.29View SEC Filing  
12/17/2014& Johnson JohnsonMajor ShareholderSell8,100$7.62$61,722.00View SEC Filing  
12/12/2014& Johnson JohnsonMajor ShareholderSell5,000$7.51$37,550.00View SEC Filing  
12/10/2014& Johnson JohnsonMajor ShareholderSell8,300$7.72$64,076.00View SEC Filing  
12/9/2014& Johnson JohnsonMajor ShareholderSell5,000$7.73$38,650.00View SEC Filing  
12/8/2014& Johnson JohnsonMajor ShareholderSell2,000$7.69$15,380.00View SEC Filing  
12/5/2014& Johnson JohnsonMajor ShareholderSell15,900$7.76$123,384.00View SEC Filing  
12/1/2014& Johnson JohnsonMajor ShareholderSell1,200$7.54$9,048.00View SEC Filing  
11/26/2014& Johnson JohnsonMajor ShareholderSell2,000$7.75$15,500.00View SEC Filing  
11/24/2014& Johnson JohnsonMajor ShareholderSell9,500$8.14$77,330.00View SEC Filing  
3/12/2014Pfizer IncMajor ShareholderBuy272,727$11.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Latest Headlines for Aquinox Pharmaceuticals (NASDAQ:AQXP)
DateHeadline logoAnalyzing the Financial Health of Biotech Companies - PR Newswire (press release) - August 17 at 10:27 PM logoAquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to "Hold" - August 15 at 4:52 PM logoAquinox Pharmaceuticals, Inc. (AQXP) Raised to Buy at Zacks Investment Research - August 10 at 4:32 PM logoFY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Increased by Analyst - August 10 at 1:50 PM logoAquinox Pharmaceuticals' (AQXP) CEO David Main on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 8 at 3:52 PM logoAquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - GlobeNewswire (press release) - August 8 at 3:52 PM logoInvestor Network: Aquinox Pharmaceuticals, Inc. to Host Earnings Call - August 8 at 3:52 PM logoAquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - August 8 at 3:51 PM logoAquinox reports 2Q loss - August 8 at 3:51 PM logoAquinox Pharmaceuticals, Inc. (AQXP) Issues Earnings Results - August 8 at 2:24 PM logoAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Upgraded by BidaskClub to "Hold" - August 6 at 1:56 PM logoZacks: Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) to Post -$0.59 EPS - August 5 at 7:08 AM logoAquinox to Present at Canaccord Genuity 37th Annual Growth Conference - August 2 at 4:50 PM logoAquinox to Present at Canaccord Genuity 37th Annual Growth Conference - August 2 at 4:50 PM logoAquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results - August 1 at 4:59 PM logoAquinox Pharmaceuticals, Inc. (AQXP) Cut to "Sell" at BidaskClub - July 29 at 9:21 PM logoAquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Rating of "Hold" from Analysts - July 28 at 4:39 PM logoAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) to Release Earnings on Wednesday - July 26 at 7:20 AM logoAnalyzing Aquinox Pharmaceuticals (AQXP) and Teligent (TLGT) - July 19 at 8:51 AM logo Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Will Post Earnings of -$0.59 Per Share - July 13 at 10:20 PM logoAquinox Pharmaceuticals, Inc. (AQXP) Cut to Hold at Zacks Investment Research - July 11 at 5:26 PM logoCorium International (CORI) Catches Eye: Stock Jumps 11.9% - July 8 at 6:21 AM logoAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Given Average Rating of "Buy" by Brokerages - July 3 at 4:58 PM logoContrasting Theravance Biopharma (TBPH) and Aquinox Pharmaceuticals (AQXP) - June 26 at 2:26 PM logo Brokerages Expect Aquinox Pharmaceuticals, Inc. (AQXP) Will Announce Earnings of -$0.59 Per Share - June 19 at 10:28 PM logoAquinox Pharmaceuticals, Inc. (AQXP) Upgraded to "Hold" at ValuEngine - June 13 at 1:00 AM logoAquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Analysts - June 6 at 2:38 PM logoInsider Selling: Aquinox Pharmaceuticals Inc (AQXP) Insider Sells 15,625 Shares of Stock - June 5 at 8:07 PM logoSupernus Pharmaceuticals (SUPN) Jumps: Stock Rises 6.2% - June 1 at 3:50 PM logoAquinox to Present at Jefferies 2017 Global Healthcare Conference - June 1 at 3:50 PM logoAquinox Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.24) Per Share (AQXP) - May 15 at 8:54 AM logoShort Interest in Aquinox Pharmaceuticals Inc (AQXP) Declines By 19.6% - May 14 at 9:14 AM logoAquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Brokerages - May 12 at 2:38 PM logoAquinox Pharmaceuticals Inc (AQXP) Upgraded to Buy by Zacks Investment Research - May 11 at 10:52 PM logoBRIEF-Aquinox Pharmaceuticals Qtrly loss per share $0.36 - May 11 at 3:59 PM logoResearch Analysts Issue Forecasts for Aquinox Pharmaceuticals Inc's FY2017 Earnings (AQXP) - May 11 at 11:42 AM logoAquinox Pharmaceuticals Inc (AQXP) Given a $28.00 Price Target by Cantor Fitzgerald Analysts - May 9 at 11:36 PM logoZacks Investment Research Downgrades Aquinox Pharmaceuticals Inc (AQXP) to Hold - May 9 at 4:38 PM logoAquinox Pharmaceuticals Announces First Quarter 2017 Financial Results - May 9 at 3:35 PM logoAquinox reports 1Q loss - May 9 at 3:35 PM logoAquinox Pharmaceuticals Inc (AQXP) Announces Earnings Results, Beats Estimates By $0.15 EPS - May 9 at 11:24 AM logoAquinox Pharmaceuticals Inc (AQXP) to Release Quarterly Earnings on Monday - May 5 at 11:12 PM logoAquinox Pharmaceuticals Inc (AQXP) Scheduled to Post Quarterly Earnings on Monday - May 5 at 10:46 PM logoAquinox Pharmaceuticals Inc (AQXP) Scheduled to Post Earnings on Monday - May 5 at 10:23 PM logoAquinox Pharmaceuticals (AQXP) Earns News Sentiment Rating of 0.10 - May 2 at 7:26 PM logoZacks: Brokerages Expect Aquinox Pharmaceuticals Inc (AQXP) to Announce -$0.57 Earnings Per Share - May 1 at 7:46 PM logoAquinox Pharmaceuticals (AQXP) Given Daily Coverage Optimism Rating of 0.04 - April 27 at 2:42 PM logoAquinox to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference - April 26 at 8:58 AM logoAquinox Pharmaceuticals (AQXP) Receives Daily News Sentiment Score of 0.02 - April 23 at 8:22 AM logoSomewhat Favorable Media Coverage Very Unlikely to Affect Aquinox Pharmaceuticals (AQXP) Share Price - April 20 at 2:40 PM



Aquinox Pharmaceuticals (AQXP) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by Staff